Published in Muscle Nerve on December 01, 1998
Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry (2004) 1.79
Psychogenic facial movement disorders: clinical features and associated conditions. Mov Disord (2012) 0.94
Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm (Vienna) (2007) 0.93
Influence of coffee drinking and cigarette smoking on the risk of primary late onset blepharospasm: evidence from a multicentre case control study. J Neurol Neurosurg Psychiatry (2007) 0.85
Hemifacial spasm: conservative and surgical treatment options. Dtsch Arztebl Int (2012) 0.85
Microvascular decompression for hemifacial spasm associated with the vertebral artery. Neurosurg Rev (2012) 0.83
Three-dimensional MR volumetric analysis of the posterior fossa CSF space in hemifacial spasm. Neurology (2009) 0.83
Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport. J Neural Transm (Vienna) (2010) 0.83
Botulinum toxin in hemifacial spasm: the challenge to assess the effect of treatment. J Neural Transm (Vienna) (2012) 0.83
The significance of intraoperative electromyographic "lateral spread" in predicting outcome of microvascular decompression for hemifacial spasm. J Neurol Surg B Skull Base (2014) 0.83
Abnormal muscle responses in hemifacial spasm: F waves or trigeminal reflexes? J Neurol Neurosurg Psychiatry (2006) 0.82
Familial hemifacial spasm and determinants of late onset. Neurol Sci (2009) 0.81
Distinguishing features of psychogenic (functional) versus organic hemifacial spasm. J Neurol (2016) 0.81
The effect of bangerter occlusion foils on blepharospasm and hemifacial spasm in occlusion-positive and occlusion-negative patients. Open Ophthalmol J (2010) 0.80
Hemifacial Spasm due to Compression of the Posterior Inferior Cerebellar Artery Aneurysm Treated with Botulinum Toxin Type-A: A Case Report. Case Rep Neurol Med (2012) 0.79
A case of hemifacial spasm caused by an artery passing through the facial nerve. J Korean Neurosurg Soc (2015) 0.78
Hemifacial spasm and neurovascular compression. ScientificWorldJournal (2014) 0.77
Hemifacial spasm non-motor and motor-related symptoms and their response to botulinum toxin therapy. J Neural Transm (Vienna) (2010) 0.77
Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment. Neurol Sci (2016) 0.76
Sexual Well-Being in Patients with Blepharospasm, Spasmodic Torticollis, and Hemifacial Spasm: A Pilot Study. Front Psychol (2016) 0.75
A Rare Cause of Hemifacial Spasm: Papillary Oncocytic Cystadenoma. Balkan Med J (2016) 0.75
Facial nerve compression by the posterior inferior cerebellar artery causing facial pain and swelling: a case report. J Med Case Rep (2014) 0.75
Clinical and electrophysiological studies of botulinum toxin type A to treat hemifacial spasm complicated with auricular symptoms. Int J Clin Exp Med (2015) 0.75
Hemifacial spasm due to vertebrobasilar dolichoectasia: a case report. Radiol Case Rep (2015) 0.75
Revisiting the link between hypertension and hemifacial spasm. Sci Rep (2016) 0.75
Botulinum toxin in hemifacial spasm: Revisited. Indian J Plast Surg (2013) 0.75
Microvascular decompression for familial hemifacial spasm : single institute experience. J Korean Neurosurg Soc (2013) 0.75
Altered spontaneous brain activity in patients with hemifacial spasm: a resting-state functional MRI study. PLoS One (2015) 0.75
Vascular tortuosity in relationship with hypertension and posterior fossa volume in hemifacial spasm. BMC Neurol (2016) 0.75
Nonspastic hemifacial spasm confirmed by abnormal muscle responses. Surg Neurol Int (2017) 0.75
Hemifacial spasm associated with type 1 Chiari malformation: a retrospective study of 13 cases. Neurosurg Rev (2016) 0.75
Functional end-plate recovery in long-term botulinum toxin therapy of hemifacial spasm: a nerve conduction study. Neurol Sci (2012) 0.75
Treatment of Blepharospasm/Hemifacial Spasm. Curr Treat Options Neurol (2017) 0.75
Tremor in hemifacial spasm patients. J Neural Transm (Vienna) (2010) 0.75
Tenth case of bilateral hemifacial spasm treated by microvascular decompression: Review of the pathophysiology. Surg Neurol Int (2017) 0.75
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol (1989) 2.91
Essential tremor: clinical correlates in 350 patients. Neurology (1991) 2.89
Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA (2001) 2.79
Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology (2004) 2.70
The morbidity and mortality of vermiculite miners and millers exposed to tremolite-actinolite: Part I. Exposure estimates. Am J Ind Med (1987) 2.66
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology (2003) 2.65
Paroxysmal kinesigenic dyskinesia and infantile convulsions: clinical and linkage studies. Neurology (2000) 2.48
Psychogenic myoclonus. Neurology (1993) 2.39
Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology (1987) 2.38
The impact of depressive symptoms in early Parkinson disease. Neurology (2007) 2.37
Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA (2001) 2.36
Paroxysmal dyskinesias: clinical features and classification. Ann Neurol (1995) 2.21
Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's disease: postoperative magnetic resonance imaging analysis. J Neurosurg (1997) 2.15
Delayed-onset progressive movement disorders after static brain lesions. Neurology (1996) 1.96
Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology (2001) 1.94
Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology (1982) 1.88
Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol (1983) 1.87
Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology (1997) 1.86
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 1.80
Extrapyramidal involvement in Rett's syndrome. Neurology (1990) 1.74
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology (2007) 1.68
Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience (2009) 1.67
The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology (1985) 1.65
A variant in the HS1-BP3 gene is associated with familial essential tremor. Neurology (2005) 1.63
The alien hand and related signs. J Neurol Neurosurg Psychiatry (1992) 1.62
Orthostatic tremor: an association with essential tremor. Mov Disord (1991) 1.58
Intrathecal baclofen for intractable axial dystonia. Neurology (1991) 1.58
What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology (1997) 1.58
Tardive oculogyric crises. Neurology (1989) 1.56
Segmental myoclonus. Clinical and pharmacologic study. Arch Neurol (1986) 1.56
Pallidotomy for generalized dystonia. Mov Disord (1998) 1.54
Hemidystonia: a report of 22 patients and a review of the literature. J Neurol Neurosurg Psychiatry (1985) 1.52
Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology (2001) 1.52
Effects of visual and auditory cues on gait in individuals with Parkinson's disease. J Neurol Sci (2004) 1.50
Bruxism in Huntington's disease. Mov Disord (2000) 1.49
Treatment of palatal myoclonus with sumatriptan. Mov Disord (1996) 1.48
Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med (1989) 1.46
Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord (1989) 1.44
Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci (1997) 1.43
Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry (2005) 1.42
Genome-wide association study of Tourette's syndrome. Mol Psychiatry (2012) 1.42
Cervical dystonia as the initial presentation of Huntington's disease. Mov Disord (1996) 1.39
Treating severe bruxism with botulinum toxin. J Am Dent Assoc (2000) 1.38
Blepharospasm associated with brainstem lesions. Neurology (1983) 1.37
What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol (1997) 1.35
Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology (2005) 1.34
Association between essential tremor and Parkinson's disease. Ann Neurol (1985) 1.33
Botulinum toxin injection of the vocal fold for spasmodic dysphonia. A preliminary report. Arch Otolaryngol Head Neck Surg (1987) 1.33
Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology (1996) 1.32
Physiologic and pathologic tremors. Diagnosis, mechanism, and management. Ann Intern Med (1980) 1.28
Relationship of aging to Parkinson's disease. Adv Neurol (1987) 1.28
Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology (2004) 1.28
Focal task-specific tremor and dystonia: categorization of occupational movement disorders. Neurology (1988) 1.26
Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. Acta Neurol Scand (2006) 1.26
Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry (1998) 1.25
Lower body parkinsonism: evidence for vascular etiology. Mov Disord (1989) 1.24
Low cancer rates among patients with Parkinson's disease. Ann Neurol (1985) 1.24
Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology (1999) 1.23
Movement disorders and AIDS. Neurology (1987) 1.23
Late-onset Hallervorden-Spatz disease presenting as familial parkinsonism. Neurology (1985) 1.21
Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem (1999) 1.21
Blinking and blepharospasm. Mechanism, diagnosis, and management. JAMA (1982) 1.19
Stiff-person syndrome: an autoimmune disease. Mov Disord (1991) 1.19
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology (1999) 1.19
Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry (2007) 1.18
Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics (2001) 1.18
Clinical correlates of vascular parkinsonism. Arch Neurol (1999) 1.18
Herpes zoster ophthalmicus followed by contralateral hemiparesis: report of two cases and review of literature. J Neurol Neurosurg Psychiatry (1985) 1.17
Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology (2006) 1.17
Criteria for the diagnosis of essential tremor. Neurology (2000) 1.17
Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry (1998) 1.15
Rett syndrome and associated movement disorders. Mov Disord (1990) 1.15
Laterality and symptom association in Parkinson's disease. Arch Neurol (1985) 1.15
Variability and validity of polymorphism association studies in Parkinson's disease. Neurology (2000) 1.14
Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology (1997) 1.12
Good communication in psychiatry--a conceptual review. Eur Psychiatry (2011) 1.12
Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson's disease tremor. Neurology (1998) 1.11
Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol (1982) 1.09
Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp Neurol (1999) 1.09
CAG repeat size and clinical presentation in Huntington's disease. Neurology (1994) 1.09
Surgery for Parkinson disease and other movement disorders: benefits and limitations of ablation, stimulation, restoration, and radiation. Arch Neurol (2001) 1.08
Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology (2002) 1.08
Revisiting the relationship between essential tremor and Parkinson's disease. Mov Disord (2011) 1.07
Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord (2000) 1.07
Restless legs syndrome: clinicoetiologic correlates. Neurology (1996) 1.07
Essential tremor and PD. Neurology (1993) 1.07
GPi deep brain stimulation for Tourette syndrome improves tics and psychiatric comorbidities. Neurology (2007) 1.07
Hearing impairment in essential tremor. Neurology (2003) 1.07
Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol (1995) 1.06
Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol (1983) 1.06
Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett (2000) 1.04
Severe motor tics causing cervical myelopathy in Tourette's syndrome. Mov Disord (1996) 1.04
Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol (1984) 1.03
Metoclopramide-induced phantom dyskinesia. Neurology (1985) 1.03
Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry (1999) 1.02
Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology (1998) 1.02
Benign coital cephalalgia. Differential diagnosis and treatment. Arch Neurol (1981) 1.01
LINGO1 variants in essential tremor and Parkinson's disease. Acta Neurol Scand (2011) 0.99